Ascentage Pharma Group International (AAPGV) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to Ascentage Pharma Group International (AAPGV) stock?
Ascentage Pharma Group International (AAPGV) no longer trades on public markets. The figures below are historical and are not a current quote.
Beta 1.10: the stock has moved about 10% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Ascentage Pharma Group International (AAPGV). Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases. Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for AAPGV: AAPGV does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AAPGV against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Dated analysis: the newest financial statements on file are 27 months old (Jun 1, 2024), so the figures and score below describe that period, not today.
AAPGV: 1/2 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Ascentage Pharma Group International (AAPGV) Healthcare & Pipeline Overview
Ascentage Pharma Group International is a clinical-stage biotechnology firm specializing in innovative therapies for cancers, HBV, and age-related ailments, primarily in Mainland China. Their pipeline includes HQP1351, a BCR-ABL inhibitor, and other novel treatments targeting critical pathways in hematologic malignancies and solid tumors, positioning them in the competitive biotechnology landscape.
What Is the Investment Thesis for AAPGV?
The company's lead asset, HQP1351, addresses BCR-ABL mutants, including the challenging T315I mutation. Further value drivers include APG-2575, APG-115, and APG-1252, each targeting critical pathways in cancer development. Key catalysts include clinical trial readouts for these assets, potential regulatory approvals, and strategic partnerships. However, the company's negative profit margin of -296.8% and reliance on future product commercialization pose significant risks. Success hinges on positive clinical data, regulatory success, and effective market access strategies.
Based on FMP financials and quantitative analysis
AAPGV Key Highlights
Market capitalization of $0.13 billion reflects the company's current valuation in the biotechnology sector.
- Negative P/E ratio of -12.42 indicates that the company is currently not profitable.
- Gross margin of 90.9% suggests strong potential profitability upon commercialization of its drug candidates.
- Profit margin of -296.8% highlights the significant R&D expenses associated with clinical-stage biotechnology companies.
- Beta of 1.10 indicates that the stock is slightly more volatile than the market.
Who Are AAPGV's Competitors?
AAPGV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ATYR aTyr Pharma, Inc. | $0.43 | -5.16% | $42.4M | — |
| BCYP Big Cypress Acquisition Corp. | $8.44 | -19.23% | $425M | — |
| CYT Cyteir Therapeutics, Inc. | $3.02 | -2.27% | $109M | — |
| DBTX Decibel Therapeutics, Inc. | $4.91 | -0.81% | $123M | — |
| GRAY Graybug Vision, Inc. | $5.50 | -10.80% | $121M | — |
| NVO Novo Nordisk A/S | $44.01 | -1.23% | $195B | 925-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $514.90 | +0.07% | $131B | 965-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $793.26 | -1.78% | $81.7B | 945-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AAPGV's Key Strengths?
Innovative pipeline of clinical-stage drug candidates.
- Proprietary technology platform for small molecule inhibitor design.
- Strong intellectual property protection.
- Experienced management team with expertise in drug development.
What Are AAPGV's Weaknesses?
Negative profitability and reliance on future product commercialization.
- High R&D expenses associated with clinical-stage development.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Limited commercial infrastructure.
What Could Drive AAPGV Stock Higher?
Clinical trial readouts for HQP1351 in chronic myeloid leukemia (CML).
- Regulatory submissions for APG-2575 in hematologic malignancies.
- Expansion of strategic partnerships and collaborations.
- Advancement of APG-115 into later-stage clinical trials.
- Development of new drug candidates targeting age-related diseases.
What Are the Key Risks for AAPGV?
Financial-distress signal — its Altman Z-Score of -3.31 sits in the distress zone (elevated bankruptcy risk).
- Clinical trial failures and regulatory setbacks.
- Competition from established pharmaceutical companies and emerging biotech firms.
- High R&D expenses and negative profitability.
- Dependence on successful product commercialization.
- Patent expirations and generic competition.
What Are the Growth Opportunities for AAPGV?
- Expansion of HQP1351: HQP1351, Ascentage's lead product candidate, presents a significant growth opportunity by targeting BCR-ABL mutants, including those with the T315I mutation. The market for targeted therapies in chronic myeloid leukemia (CML) is substantial, and HQP1351's potential to overcome resistance to existing treatments positions it for significant market penetration. Successful clinical trials and regulatory approvals in key markets, including China and the United States, could drive substantial revenue growth over the next 3-5 years.
- Development of APG-2575: APG-2575, an orally administered Bcl-2 selective inhibitor, represents a promising growth avenue in hematologic malignancies and solid tumors. The Bcl-2 inhibitor market is expanding, with increasing recognition of its role in cancer cell survival. Positive clinical data demonstrating efficacy and safety could lead to regulatory approvals and commercialization within the next 4-6 years, capturing a share of the growing market for targeted cancer therapies.
- Advancement of APG-115: APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions, offers a growth opportunity in treating solid tumors and hematological malignancies. The MDM2-p53 pathway is a critical target in cancer therapy, and APG-115's potential to restore p53 function could lead to significant clinical benefits. Successful clinical trials and regulatory approvals could drive commercialization within the next 5-7 years, addressing a substantial unmet need in cancer treatment.
- Strategic Partnerships and Collaborations: Ascentage Pharma can leverage strategic partnerships and collaborations with biotechnology and pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Collaborations can provide access to additional funding, expertise, and market access, enhancing the company's growth prospects. Successful partnerships could lead to revenue-sharing agreements and milestone payments, contributing to long-term growth and profitability.
- Expansion into New Therapeutic Areas: Ascentage Pharma can explore opportunities to expand its pipeline into new therapeutic areas beyond oncology, such as age-related diseases and chronic HBV infection. These areas represent significant unmet medical needs and potential growth markets. By leveraging its expertise in drug discovery and development, Ascentage can diversify its pipeline and create new revenue streams over the long term. This strategic diversification could mitigate risks associated with reliance on a single therapeutic area.
What Are AAPGV's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Expertise in small molecule inhibitor design and development.
- Established clinical development capabilities.
- Strategic collaborations with biotechnology and pharmaceutical companies.
What Does AAPGV Do?
Founded in 2009 and headquartered in Suzhou, China, Ascentage Pharma Group International is a clinical-stage biotechnology company dedicated to discovering, developing, and commercializing innovative therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases. The company's lead product candidate is HQP1351, a BCR-ABL inhibitor designed to target BCR-ABL1 mutants, including those with the T315I mutation, which often confers resistance to existing treatments. Ascentage Pharma is also developing a diverse pipeline of drug candidates, including APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors, and APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies. Furthermore, the company is advancing APG-1252, a small molecule drug designed to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. Ascentage Pharma's commitment extends to medical research and development, clinical development, and clinical trial operations, with collaborations established with biotechnology and pharmaceutical companies, as well as research institutions. This comprehensive approach underscores their mission to address unmet medical needs and improve patient outcomes.
What Products and Services Does AAPGV Offer?
- Develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases.
- Focuses on small molecule inhibitors targeting key pathways in cancer development.
- Conducts medical research and development to identify novel drug candidates.
- Manages clinical development programs to evaluate the safety and efficacy of its therapies.
- Operates clinical trials to generate data for regulatory submissions.
- Engages in venture capital investment to support innovation in the biotechnology sector.
- Provides rental services and science and technology promotion services.
How Does AAPGV Make Money?
- Develops and patents novel drug candidates targeting specific disease pathways.
- Conducts preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approvals from agencies such as the FDA and EMA.
- Commercializes approved drugs through its own sales force or through partnerships with other pharmaceutical companies.
What Industry Does AAPGV Operate In?
Ascentage Pharma operates within the dynamic and competitive biotechnology industry, characterized by rapid innovation, stringent regulatory requirements, and high capital intensity. Ascentage competes with established pharmaceutical giants and emerging biotech firms, including ATYR Pharma, BCYP, CYT, DBTX, and GRAY, all vying for market share in targeted therapies. Success in this landscape requires robust clinical data, strategic partnerships, and efficient commercialization strategies.
Who Are AAPGV's Key Customers?
- Patients suffering from cancers, chronic hepatitis B virus (HBV), and age-related diseases.
- Hospitals and clinics that administer Ascentage Pharma's therapies.
- Pharmaceutical companies that may partner with Ascentage Pharma to develop and commercialize its drugs.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● Latest filing 620 days ago
- ● No analyst coverage
- ● Reported in CNY, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 4 snapshots
| 2026-08-23 | 46 |
| 2026-08-24 | 46 |
| 2026-08-25 | 46 |
| 2026-08-26 | 46 |
What changed?
The score has stayed at 46.
Over the same 3 days the stock moved +0.0%.
Key Financial Metrics
Return on assets is -31.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.79 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.3%, the inverse of the P/E and a quick read on earnings relative to price.
AAPGV Revenue & Earnings Trend
In Q4 FY2024, AAPGV generated $12.2M in top-line revenue, marking a sequential decrease of 80.2%. The company recorded a net loss of $44.1M, with diluted EPS of $-0.14.
Company Profile
Ascentage Pharma Group International operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Suzhou, CN. The company is led by CEO Dajun Yang. AAPGV has traded publicly since 2025.
Financial Health
Ascentage Pharma Group International's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -3.31 places it in the distress zone, a signal of elevated financial risk.
AAPGV Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Innovative pipeline of clinical-stage drug candidates.
- Proprietary technology platform for small molecule inhibitor design.
- Strong intellectual property protection.
- Experienced management team with expertise in drug development.
Bear Case
- Negative profitability and reliance on future product commercialization.
- High R&D expenses associated with clinical-stage development.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Limited commercial infrastructure.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 FY2024 | $12M | -$44M | -$0.14 |
| Q2 FY2024 | $61M | $12M | $0.04 |
Q4 FY2024 · filed 31 Dec 2024 · SEC EDGAR →
Based on FMP financials and quantitative analysis · Converted to USD from CNY at today's rate
AAPGV Latest News
No recent news available for AAPGV.
Leadership: Dajun Yang
CEO
Dajun Yang is the CEO of Ascentage Pharma Group International. His background includes extensive experience in the pharmaceutical and biotechnology industries. He has a proven track record in drug development, clinical trials, and commercialization. Yang's expertise spans various therapeutic areas, including oncology, virology, and age-related diseases. He has held leadership positions in several multinational pharmaceutical companies, contributing to the development and launch of multiple successful products. His educational background includes advanced degrees in chemistry and pharmacology.
Track Record: Under Dajun Yang's leadership, Ascentage Pharma has advanced its pipeline of drug candidates through clinical development, achieving key milestones in regulatory submissions and strategic partnerships. He has overseen the expansion of the company's research and development capabilities, strengthening its position in the biotechnology sector. Yang has also played a crucial role in securing funding and investments to support the company's growth initiatives.
AAPGV OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ascentage Pharma Group International may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, minimal assets, or are undergoing financial distress. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and information transparency compared to exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before considering an investment in AAPGV.
- OTC Tier: OTC Other
- Limited information disclosure due to lower regulatory requirements.
- Higher potential for fraud and manipulation compared to listed exchanges.
- Greater price volatility and illiquidity.
- Increased risk of delisting or trading suspensions.
- Potential for limited access to company management and information.
- Verify the company's legal status and registration.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the company's capital structure and ownership.
- Determine the level of trading volume and liquidity.
- Consult with a qualified financial advisor.
- Established partnerships with reputable biotechnology or pharmaceutical companies.
- Positive clinical trial results for its drug candidates.
- Experienced management team with a proven track record.
- Patent protection for its key technologies.
- Independent audits of its financial statements (if available).
What Investors Ask About Ascentage Pharma Group International (AAPGV) — Healthcare
What happened to Ascentage Pharma Group International (AAPGV) stock?
Ascentage Pharma Group International (AAPGV) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy AAPGV shares?
No. AAPGV stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for AAPGV elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before AAPGV stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Ascentage Pharma Group International. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Ascentage Pharma Group International do?
Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing innovative therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases.
What are the main risks for AAPGV?
Ascentage Pharma faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as negative results could delay or halt the development of its drug candidates.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.